- Home
- CLLS vs AUTL Comparison
CLLS vs AUTL Comparison
Compare CLLS & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLLS | AUTL |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | France | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 384.3M | 407.2M |
| IPO Year | 2014 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CLLS | AUTL |
|---|---|---|
| Price | $3.91 | $1.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $8.33 | ★ $8.50 |
| AVG Volume (30 Days) | 26.7K | ★ 1.3M |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $80.32 |
| Revenue Next Year | $0.98 | $53.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $1.33 | $1.15 |
| 52 Week High | $5.48 | $2.70 |
Technical Indicators
Market Signals| Indicator | CLLS | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 47.05 | 56.28 |
| Support Level | $3.39 | $1.22 |
| Resistance Level | $3.83 | $1.69 |
| Average True Range (ATR) | 0.17 | 0.08 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 7.38 | 57.63 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.